|
|
Summary ToggleZafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer
Ms. Allen Brings Significant Public Company Experience as Zafgen Continues to Evaluate its Strategic Options
|
Summary ToggleZafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer
|
|
|
Summary ToggleZafgen Secures $21 Million in Series D Financing
Alta Partners Joins Investor Syndicate to Lead New Funding<br /><br />Proceeds to Advance Development of Obesity Therapeutic Beloranib
|
Summary ToggleZafgen Secures $21 Million in Series D Financing
|
|
|
Summary ToggleZafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
|
Summary ToggleZafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
|
|
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society
Findings Show Treatment with Beloranib Resulted in Rapid Weight Loss, Corresponding Reductions in Multiple Cardiovascular Risk Factors in Severely Obese Subjects
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society
|
|
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®
Results Show Treatment with Beloranib Resulted in Weight Loss and Corresponding Reductions in Multiple Cardiometabolic Risk Factors in Severely Obese Subjects
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®
|
|
|
Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors
|
Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors
|
|
|
Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting
|
Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting
|
|
|
Summary ToggleZafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer
|
Summary ToggleZafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer
|
|
|
Summary ToggleZafgen Secures $33 Million Series C Financing
Proceeds to Advance Zafgen’s Lead Compound for Severe Obesity into Phase 2 Clinical Studies
|
Summary ToggleZafgen Secures $33 Million Series C Financing
|
|
|
Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
Results Show MetAP2 Inhibitor Treatment Improves Cardiovascular Risk Markers in Severely Obese Subjects
Company Also Announces Initiation of Dose Escalation Trial in Obese Women
|
Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
|